|
Optimizing the Engineering of CAR-T Cells
Application
A method for selecting distinct T cell populations in order to generate more effective CAR-T cells.
Key Benefits
The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells.
This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 7/26/2024
Contributor(s): Byron Au-Yeung
|
|
Advancing Lymphatic Endothelial Cell Generation from iPSCs
Application
The developed protocol offers a reproducible and scalable method for generating lymphatic endothelial cells (LECs) from induced pluripotent stem cells (iPSCs), addressing critical challenges in the field of lymphatic-related therapies.
Key Benefits
Reproducible and scalable protocol for generating LECs from iPSCs.
Utilizes specific...
Published: 7/26/2024
Contributor(s): Katherine Hekman, Katherine Owsiany
|
|
Therapeutic for Potential Elimination of Chronic Hepatitis B
Application
A therapeutic technique to eliminate infection of patients suffering from chronic Hepatitis B Virus infection.
Key Benefits
May provide a cure for chronic HBV infection rather than just simple management.
High efficiency of infection targeting may produce minimal side effects.
May be used in combination with other HBV inhibitors.
Market...
Published: 7/26/2024
Contributor(s): Raymond Schinazi, Leda Bassit, Ting Nie
|
|
Methods for Enhancing MSC Therapeutic Potential for Treatment of Osteoarthritis by Measuring and Targeting Intracellular Pathways
Application
Highly transformative new strategy to enhance mesenchymal stromal cell consistency and efficacy for taking MSC therapies to clinical stage.
Key Benefits
Currently there is no method to determine if an MSC donor line will be therapeutically effective.
Provides a point of use assay in the clinical setting which can determine MSC efficacy...
Published: 7/26/2024
Contributor(s): Nick Willett, Levi Wood, Jay McKinney
|
|
Tumor Specific CD8 T Cell TCR Sequences of HPV-Positive Head and Neck Tumors
Application
HPV-specific CD8 TCR sequences for the treatment of HPV-positive head and neck cancer by adoptive cell therapy.
Key Benefits
HPV tumor antigen set is specific for HPV-positive head and neck cancer.
Targeting of ‘non-classical’ HPV antigens E2 and E5.
Potential to synergize and complement HPV E6/7-specific TCR therapies...
Published: 7/19/2024
Contributor(s): Rafi Ahmed, Christiane Eberhardt, Andreas Wieland
|
|
Isolation of Therapeutic cells and Framework for Adoptive Cell Therapies
Application
Isolation of therapeutic cells and framework for adoptive cell therapies based around stem-like chronic memory CD8 T cells that may be paired with PD-1 blockade.
Key Benefits
Persistent cell survival and therapeutic efficacy following rechallenge with chronic viral infection and cancer.
Strong co-treatment potential with PD-1...
Published: 7/19/2024
Contributor(s): Rafi Ahmed, Daniel Chang
|
|
High-Throughput Platform for Imaging and Maintaining Cells in Culture
Application
This closed-loop platform monitors and maintains traditional cell culture and bioengineered tissues to automate standard and custom cell maintenance protocols, including stem cell differentiations, bioengineered tissue generation, and functional maturation of complex cell cultures.
Key Benefits
Automation of cell culture maintenance
Integration...
Published: 7/26/2024
Contributor(s): Vahid Serpooshan, Ayda Melika, Amir Pourmorteza
|
|
CRISPR Based System for Targeted Reduction of Gene Expression
Application
A CRISPR based gene silencing system using sequence specific RNA to repress expression of endogenous transcripts.
Key Benefits
Provides a platform to target specific mRNA transcripts in both prokaryotic and eukaryotic cells.
Potential therapeutic strategy against pathogenic bacteria and viruses.
Market Summary
RNAi is an indispensable...
Published: 4/23/2024
Contributor(s): David Weiss, Timothy Sampson
|
|
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application
Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition.
Key Benefits
Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors.
Checkpoint inhibitor therapy is FDA-approved and already in use.
Market Summary
Checkpoint blockade...
Published: 7/26/2024
Contributor(s): Eric J. Sorscher, Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 4/23/2024
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|